Aprea Therapeutics (NASDAQ:APRE) Trading Down 2.5% – What’s Next?

Aprea Therapeutics, Inc. (NASDAQ:APRE) shares traded down 2.5% during mid-day trading on Tuesday . The stock traded as low as $0.65 and last traded at $0.6520. 43,647 shares changed hands during mid-day trading, a decline of 33% from the average daily volume of 65,580 shares. The stock had previously closed at $0.6690.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on APRE. Wedbush lowered their target price on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Friday, July 17th. HC Wainwright dropped their target price on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Oppenheimer began coverage on Aprea Therapeutics in a report on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.07.

Aprea Therapeutics Stock Performance

The stock’s fifty day moving average price is $0.78 and its 200-day moving average price is $0.80. The firm has a market cap of $8.08 million, a PE ratio of -0.42 and a beta of 1.50.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Wednesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 61.03%. Sell-side analysts forecast that Aprea Therapeutics, Inc. will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aprea Therapeutics

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Aprea Therapeutics during the fourth quarter worth $40,000. DRW Securities LLC acquired a new stake in Aprea Therapeutics in the fourth quarter valued at $103,000. Finally, AIGH Capital Management LLC increased its position in shares of Aprea Therapeutics by 174.1% in the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock valued at $775,000 after buying an additional 645,000 shares in the last quarter. 34.19% of the stock is owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.